President amends Drugs Act to allow methylphenidate for ADHD treatment

Methylphenidate is a stimulant medication commonly prescribed worldwide to help manage symptoms of ADHD, including inattention, hyperactivity and impulsivity.

Mohamed Hilmy

12 May 2026, 12:37

President Dr Mohamed Muizzu has issued a decree amending the Drugs Act to facilitate the availability of methylphenidate as a first-line treatment for Attention Deficit Hyperactivity Disorder (ADHD) in the Maldives.

The amendment came into effect through Presidential Decree No. 10/2026, issued under Section 3-4(e) of the Drugs Act (Act No. 17/2011) and published in the Government Gazette on Tuesday.

According to the President’s Office, the amendment was introduced following a recommendation by the National Drug Control Council and later deliberated by the Cabinet.

After receiving Cabinet approval, the proposal was submitted to the People’s Majlis in line with Section 3-4(c) of the Drugs Act. Parliament approved the removal of methylphenidate from Item No. 89 of the list of prohibited drugs under Schedule I of the Act during the 17th sitting of the first session of the People’s Majlis held on May 11, 2026.

The amendment now provides a legal framework for the availability of methylphenidate in the Maldives as a first-line treatment option for individuals diagnosed with ADHD.

Methylphenidate is a stimulant medication commonly prescribed worldwide to help manage symptoms of ADHD, including inattention, hyperactivity and impulsivity.

President amends Drugs Act to allow methylphenidate for ADHD treatment

Leave a comment

Comments

Latest News